Abstract
Objective:
This study aims to analyze the current situation and characteristics of traditional Chinese medicine for treatment of novel coronavirus pneumonia, clarify its clinical advantages and provide a reference for clinical treatment.
Methods:
Clinical randomized controlled trials, clinical control trials and case series research involving the use of Chinese medicine for novel coronavirus pneumonia treatment were selected from PubMed, Chinese Journal Service Platform of CNKI, VIP, and WanFang Data Knowledge Service Platform from the establishment of the library to 11:00 am on April 15, 2020. The published information, research design, intervention measures and research observation index were statistically analyzed.
Results:
Twenty studies were included. The research methods were mainly clinical controlled trials. The observation indicators were mostly fever improvement time, cough improvement time, shortness of breath improvement time, chest CT and CRP examination. Maxing Ganshi (Ephedrae Herba, Armeniacae Semen Amarum, Glycyrrhizae Radix Et Rhizoma, and Gypsum Fibrosum) decoction was the core prescription. The most frequently used drugs were Glycyrrhizae Radix Et Rhizoma (Gancao), Ephedrae Herba (Mahuang), Armeniacae Semen Amarum (Kuxingren), Atractylodis Rhizoma (Cangzhu), and Scutellariae Radix (Huangqin). The most frequently used drug combination was Ephedrae Herba (Mahuang)–Armeniacae Semen Amarum (Kuxingren). The most frequently used Chinese patent medicine was Lianhua Qingwen capsule/granule.
Conclusions:
Traditional Chinese medicine has widely used for novel coronavirus pneumonia in China. It is worthy of global attention. Also, high-quality randomized controlled clinical trials on the effectiveness and safety of traditional Chinese medicine in the treatment of novel coronavirus pneumonia need to carry out.
Introduction
Recently, new coronary pneumonia (NCP) outbreaks worldwide, according to the daily information released by the Chinese State and Regional Health Committees’ daily information as of 21:31 on April 16, 2020, China has confirmed a total of 83,798 cases and 3,352 cumulative deaths; among the cumulative confirmed cases of 2,019,857 worldwide, 135,165 died and 1,422,853 remained infected (). The epidemic trend in regions outside of China has greatly erupted, overseas outbreaks have escalated, and more than 20 countries and regions have been infected. Except for Antarctica, all continents have confirmed cases. How to effectively treat NCP remains a key problem. The Office of the State Administration of Traditional Chinese Medicine and the General Office of the National Health And Health Commission have issued seven editions of the “Diagnosis and Treatment Plan of Novel Coronavirus Infection Pneumonia”; each version of the diagnosis and treatment plan has always emphasized the active role of Chinese medicine in the treatment and the strengthening of its combination with Western medicine to promote medical treatment and achieve good results (). In an interview, Zhong Nanshan affirmed the role of Chinese medicine in treatment of NCP; Chinese medicine can effectively suppress inflammatory damages and can also be popularized in foreign countries (). The article aimed to systematically organize clinical research by literature metrology and data mining methods, analyze the current situation of clinical treatment research in Chinese medicine, explore the clinical treatment characteristics of Chinese medicine and provide a reference for global clinical treatment of NCP.
Materials and Methods
Search Strategy
Two reviewers (ZZ and NG) independently isolated the useful information from the database. Studies that used Chinese medicine to treat NCP were selected from PubMed, Chinese Journal Service Platform of CNKI, VIP, and WanFang Data Knowledge Service Platform. Advanced search was conducted using the following terms: “NCP” or “Novel Coronavirus Infection” or “New Coronavirus” “2019-nCoV” “COVID-19” “SARS-CoV-2” containing “Chinese and Western medicine” or “Chinese medicine” or “Traditional Chinese medicine” or “prescription.” The search time was from the establishment of the library to 11:00 on 15 April 2020.
Inclusion and Exclusion Criteria
Inclusion criteria: All studies on clinical treatment of NCP in Chinese medicine that state complete treatment options and processes and are classified as clinical control trials (CCT), randomized controlled trials (RCT), and case series studies (CS) were included.
Exclusion criteria: Studies categorized as review, basic research, regional epidemiological research, experience summary, and syndrome analysis were excluded.
Data Extraction and Analysis
Noteexpress, a document management software program, was used to manage the studies obtained from different databases. An access database was established to extract information on the publication of the literature (author, time of issue, issue journal, type of fund), research design (number of cases, subject gender and age), intervention measures (prescription, traditional Chinese medicine), research observation indicators and other information for statistical analysis. For eligible studies, two review authors (ZZ, and GN) extracted the data independently. Disagreements were resolved through consultation with a third party (FS).The law of the prescription use of Chinese medicine was analyzed statistically through the “Traditional Chinese medicine inheritance auxiliary system.”
Results
Description of Studies
We identified 757 potentially relevant articles. After removal of duplicates, 625 records remained. After going through the titles and abstracts, we exclude 605 papers. By reading the full text of the remaining 46 articles, 26 were exclude because they were case reports. Ultimately, 20 studies were included in present study (; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ). Among these studies, 2 RCTs, 10 CCTs and 8 CSs were included, which accounted for 10.00%, 50.00% and 40.00% of the total number of studies, respectively. The specific screening process is shown in Figure 1.
Figure 1
Basic Characteristics of the Literature
The basic characteristics of the 20 trials are summarized in Tables 1 and 2. The first study on clinical treatment involving Chinese medicine for treatment of NCP was published on February 6, 2020 (). After February 15, the volume of studies published began to increase. By March 25, 19 articles were published. By April 4, the volume of literature published showed a downward trend. The total number of observations was 1,810, of which 1,021 and 789 were males and females, respectively. The age ranged from 0.6 to 95 y. The largest number of subjects in the study was 308 (), and the minimum number of study cases was 13 (). About the research areas, the worst-affected area, Hubei region, had the largest volume of studies, accounting for more than 50%, followed by Henan and Anhui regions. 12 trails were funded by research projects. All trials adopted decoction or patent medicine of traditional Chinese medicine (TCM) therapy combination with western treatment in the trial group for NCP. While the control group only adopted western treatment. For the severity of included subjects, most RCTs and CCTs included subjects who were the mild or common type, while the subjects in CS were common type and serious type. Three studies mentioned death cases (; ; ). One study mentioned there were no death cases (). The other 16 studies did not mention the death condition. Adverse reactions were reported in eight studies, while no mention in the other studies. Specific research characteristics of RCTs and CCTs are shown in Table 1 and CSs are shown in Table 2.
Table 1
| Included trials | Funding | Study designs | Study region | Sample characteristics type; male/female; age(y) | Interventions | Duration | Fever improvement time(d) | Outcome index | Intergroup differences | Adverse reactions | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | Trial | Control | |||||||||
| YAO 0206 () | CCT | Hubei | CT:21 M: 16, F: 5 57.1 ± 14.0 | CT: 21 M: 12, F: 9 62.4 ± 12.3 | Chinese patent drug+WT1.2.6.7 | WT1.2.6.7 | T: 4.6 ± 3.2 C: 6.1 ± 3.1 | 1. Disappearance rate of fever and cough 2. Disappearance rate of fatigue 3. Fever improvement time 4. Disappearance rate of anhelation, expectoration 5. Disappearance rate of sore throat, choking sensation in chest, dyspnea, headache, nausea, anorexia, diarrhea, muscle pain 6. Death rate | 1.P<0.05 2.P>0.05 3.P>0.05 4.P<0.05 5.P>0.05 6.Not mentioned | |||
| LV 0217 () | CCT | Hubei | MT, CT: 63 M: 28, F: 35 59.1 ± 15.61 | MT, CT: 38 M: 18, F: 20 60.2 ± 17.01 | Chinese patent drug +WT1.2.3.5.7.8 | WT1.2.3.5.7.8 | 10 d | T: 6 (median) C: 7 (median) | 1. Disappearance rate of fever, fatigue, cough 2. Disappearance rate of anhelation, moist rale 3. Fever improvement time 4. Disappearance rate of muscle pain, expectoration, nasal obstruction, nasal discharge, sore throat, choking sensation in chest, dyspnea, headache, nausea, vomiting, anorexia, diarrhea 5. Aggravation rate 6. Death rate | 1.P<0.05 2.P<0.05 3.P>0.05 4.P>0.05 5.P>0.05 6. Not mentioned | No adverse response | |
| XIA 0218 () | √ | CCT | Hubei | CT: 27 ST: 7 M: 17, F: 17 54.18 ± 13.08 | CT: 13 ST: 5 M: 6, F: 12 53.67 ± 12.70 | decoction+WT1.2.7.8 | WT1.2.7.8 | 7–10 d | T: 2.64 ± 1.31 C: 4.38 ± 1.90 | 1. Fever improvement time 2. Recovery time of cough, fatigue, dyspnea, diarrhea) 3. Score of TCM syndrome scale 4. Incidence of mild type to severe type 5. Improvement rate of lung CT 6. Death rate | 1.P<0.01 2.P<0.01 3.P<0.05 4.<0.05 5.P>0.05 6. Trial 0%; Control 5.6% | No adverse response |
| QU 0226 () | √ | CCT | Anhui | MT, CT: 40 M: 25, F: 15 40.65 ± 8.23 | MT,CT:30 M: 16, F: 14 39.82 ± 6.40 | Chinese patent drug+WT1.2 | +WT1.2 | 10 d | T:3.24 ± 0.89 C:5.10 ± 1.40 | 1. Improvement time of temperature, dry cough, nasal obstruction, Fever improvement time, sore throat, fatigue, diarrhea 2. Dime of nucleic acid test turning negative 3. Death rate | 1.P<0.05 2.P<0.05 3. Not mentioned | Trail: 1 case of nausea; Control: 2 cases of nausea |
| DING 0303 () | RCT | Hubei | MT: 10 CT: 36 ST: 5 M: 39, F: 12 54.7 ± 21.3 | MT: 11 CT: 34 ST: 4 M: 39, F: 10 50.8 ± 23.5 | decoction+WT1.2.6 | WT1.2.6 | 10 d | 1. Disappearance rate of fever, cough, choking sensation in chest and anhelation 2. Disappearance rate of nasal obstruction, abdominal pain, and diarrhea 3. Improvement rate of ESR 4. Improvement rate of CRP, IL-6 5. Improvement rate of TNF-γ, TNF-α 6. Improvement rate of lung CT 7. Liver function 8. Death rate | 1.P<0.05 2.P>0.05 3.P<0.01 4.P<0.05 5.P>0.05 6.P<0.05 7.P>0.05 8. Not mentioned | |||
| SHI 0305 () | √ | CCT | Shanghai | MT: 1 CT: 40 ST: 8 M: 26, F: 23 47.94 ± 14.46 | MT: 1 CT: 14 ST: 3 M: 10, F: 8 46.72 ± 17.40 | Chinese patent drug+decoction+WT1.2.3.8 | WT1.2.3.8 | 6 d | T: 16 (4,42) C: 17.5 (8,42) | 1. Clinical syndrome integral 2. Hospitalization time 3. Course of disease, fever improvement time 4. Improvement rate of lung CT 5. Death rate | 1.P<0.05 2.P<0.05 3.P>0.05 4.P>0.05 5. Not mentioned | |
| XIAO 0310 () | CCT | Hubei | MT: 100 M: 64, F: 36 60.90 ± 8.70 | MT: 100 M: 66, F: 34 62.20 ± 7.50 | Chinese patent drug+WT1 | WT1 | 2 w | T: 2.25 ± 1.12 C: 3.08 ± 1.64 | 1. Total effective rate 2. Lung CT 3. Fever improvement time 4. Disappearance time of cough, fatigue, dizziness, nasal discharge 5. WBC, Lymph% 6. Death rate | 1.P<0.05 2.P<0.05 3.P<0.05 4.P>0.05 5.P<0.05 6. Not mentioned | Trail: 1 case of drug allergy: 2 cases of abdominal pain and diarrhea; Control: 2 cases of drug allergy, 1 case of abdominal pain and diarrhea | |
| CHENG 0311 () | CCT | Hubei | CT: 51 M: 26, F: 25 55.5 ± 12.3 | CT: 51 M: 27, F: 24 55.8 ± 11.6 | Chinese patent drug+WT1.2.8 | WT1.2.8 | 7 d | T:2.9 ± 1.7 C:3.9 ± 1.3 | 1. Disappearance rate and time of fever, fatigue, cough 2. Effective rate of main symptoms 3. Disappearance rate of expectoration, anhelation, choking sensation in chest, anorexia 4. Disappearance rate of muscle pain, dyspnea, nausea 5. Improvement rate of lung CT 6. Rate of turn to severe type 7. Death rate | 1.P<0.05 2.P<0.05 3.P<0.05 4.P>0.05 5.P>0.05 6.P<0.05 7. Not mentioned | ||
| FU 0320 () | √ | CCT | Hubei | CT: 37 M: 19, F: 18 45.26 ± 7.25 | CT: 36 M: 19, F: 17 44.68 ± 7.45 | Chinese patent drug+WT1.7 | WT1.7 | 10–15 d | 1. Accumulated points of fever, cough, dry throat and sore throat, choking sensation in chest and anhelation, fatigue 2. Effective rate, hospital discharge rate 3. Absolute value of LYM, CRP 4. WBC, LYM ratio 5. Death rate | 1.P<0.05 2.P<0.05 3.P<0.05 4.P>0.05 5. Not mentioned | No adverse response | |
| WANG 0323 () | √ | RCT | Hubei | MT, CT: 10 M: 5, F: 5 54.90 ± 3.71 | MT,CT:10 M:5.F:5 55.90 ± 3.71 | decoction,incense+WT1. | WT 1.2.8. | 7 d | 1. Clinical symptoms improved conditions (fatigue, cough, dry throat, short of breath) 2. Lung CT 3. Nucleic acid test turning negative 4. Death rate | 1.P<0.05 2.P>0.05 3.P>0.05 4. Not mentioned | ||
| DUAN 0324 () | √ | CCT | Hubei | MT: 82 M: 39, F: 43 51.99 ± 13.88 | MT:41 M:23.F:18 50.29 ± 13.17 | Chinese patent drug+WT1.2.6.7 | WT1.2.6.7 | 5 d | 1. Disappearance condition of fever 2. Disappearance time of fatigue, cough, expectoration, diarrhea 3. Disappearance time of aversion to cold, bodily pain, sore throat, pharyngalgia, dry throat 4. Score of TCM syndrome scale 5. Hamilton Anxiety Scale 6. Death rate | 1.P<0.01 2.P<0.05 3.P>0.05 4.P<0.01 5.P<0.01 6. Not mentioned | Trail: 27 cases of diarrhea Control: no adverse response | |
| YANG 0414 () | √ | CCT | Hubei | ST: 51 M: 28, F: 23 61.57 ± 1.84 | ST: 52 M: 24, F: 28 66.35 ± 1.82 | decoction+Chinese patent drug+WT1.2.6.7 | WT1.2.6.7 | 1. CRP 2. Albumin 3. Cases number of absorption and improvement by lung CT 4. Cure rate 5. Death rate | 1.P<0.01 2.P<0.05 3.P<0.05 4.P>0.05 5. Trial 21.6%; Control 30.77% | Trail: 2 cases of mild gastrointestinal reactions | ||
Basic characteristics of the included studies (RCT and CCT).
MT, mild type; CT, common type; ST, serious type; WT, western treatment.
WT: 1. antiviral; 2. anti-infection/anti-inflammatory/antibiotics; 3. immunoregulation; 4. gastrointestinal regulation; 5. relieving cough and asthma; 6. oxygen therapy; 7. glucocorticoid; 8. nutritional support; 9. nlgesics; 10. liver protection; 11. anti-anxiety.
Table 2
| Included trials | Funding | Study region | Sample characteristics type; male/female; age (y) | Interventions | Duration | Fever improvement time(d) | Outcome index | Self before and after comparison | Adverse reactions |
|---|---|---|---|---|---|---|---|---|---|
| CHENG 0219 () | Hubei | CT:54 M:29.F:25 60.1 ± 16.98 | Chinese patent drug+WT1.3.2.7 | 7 d | 3.6 ± 2.14 | 1. Disappearance rate of fever 2. Disappearance rate of fatigue, disappearance days of fatigue 3. Disappearance rate of cough, disappearance days of cough 4. Disappearance rate of choking sensation in chest 5. Disappearance rate of anhelation 6. Disappearance rate of anorexia 7. Disappearance rate of moist rale 8. Effective rate 9. Death rate | 1.80%, 2.75.7%, 4.1 ± 2.58 3.76.7%, 5.3 ± 2.63 4.84.6% 5.100% 6.40.0% 7.89.5% 8.81.6% 9. Not mentioned | No adverse response | |
| WANG 0228 () | Jilin | MT,CT,ST:50 M:30.F:20 44.52 ± 16.12 | decoction+WT1.2.6.7 | 7 d | 1. Total effective rate 2. Disappearance rate of aversion to cold 3. Disappearance rate of thirsty 4. Disappearance rate of fever 5. Disappearance rate of sweating 6. Disappearance rate of nasal obstruction 7. Disappearance rate of headache body ache 8. Disappearance rate of short of breath 9. Disappearance rate of nausea 10. Disappearance rate of choking sensation in chest 11. Disappearance rate of diarrhea 12. Disappearance rate of anorexia 13. Disappearance rate of expectoration 14. Disappearance rate of fatigue 15. Disappearance rate of cough 16. Death rate | 1.98.00% 2.100% 3.100% 4.96.96% 5.90.91% 6.73.33% 7.73.33% 8.72% 9.64.54% 10.64% 11.63.64% 12.55.56% 13.30.30% 14.25.93% 15.10.53% 16.0% | |||
| BIN 0229 () | √ | Hubei | MT:45 ST:10 M:31.F:24 53.9 ± 17.1 | Chinese patent drug+WT1.2.6.7 | 1. Effective rate of mild patients 2. Effective rate of severe patients 3. Death rate | 1.95.6% 2.90.0% 3.9.1% | |||
| GONG 0309 () | √ | Chongqing | CT:188 ST:37 M:125.F:100 0.6-82 | decoction+WT1.2 | 1. Lymphocyte of severe patients 2. Albumin of severe patients 3. CRP of severe patients 4. CD4+,CD8+ of severe patients 5. Death rate | 1.Gradually increase 2.Gradually increase 3.Drop to normal 4.Increase 5. Not mentioned | |||
| FANG 0312 () | √ | Hubei | MT:90 CT:98 ST:120 M:156.F:152 30-86 | decoction, Chinese patent drug+WT1.2.7 | 5.0 ± 3.8 | 1. Remaining proportion of fever 2. Improvement time and remaining proportion of diarrhea 3. Improvement time and remaining proportion of choking sensation in chest 4. Improvement time and remaining proportion of fatigue 5. Improvement time and remaining proportion of cough 6. Death rate | 1.0% 2.6.3 ± 3.8, 0% 3.8.5 ± 4.4,2.4% 4.7.1 ± 3.6,3.6% 5.10.4 ± 4.8,35.7% 6. Not mentioned | ||
| ZHU 0319 () | Jiangsu | CT:22 ST:1 M:10.F:13 50.0 ± 13.0 | Chinese patent drug+decoction+WT1.2.6.7 | 1. Absolute value of LY 2. CRP 3. Improvement rate of inflammatory change absorption of lung CT 4. Time of nucleic acid test turning negative 5. Death rate | 1.Obviously increase 2.Obviously decline 3.65.2% 4.11.6 ± 0.8 5. Not mentioned | ||||
| HU 0320 () | √ | Henan | CT:19 M:8.F:11 40.55 ± 10.59 | decoction+WT1.6 | 1. Effective rate 2. Hospitalization average time 3. Fever, cough 4. Shortness of breath, fatigue, sweating, painful abdominal mass, nausea, anorexia, diarrhea 5. Lung CT 6. Rate of turning to severe type 7. Death rate | 1.100% 2.(16.36 ± 4.95)d 3.Disappear 4.Relief 5.Obvious improvement 6.0% 7. Not mentioned | |||
| YANG 0324 () | √ | Henan | MT,CT:13 M:10,F:3 41.31 ± 13.51 | decoction+WT1.2.3.4.5 | 3 ± 0.71 | 1. Improvement time of cough 2. Improvement time of fatigue 3. Improvement time of diarrhea 4. Improvement time of choking sensation in chest 5. Lung CT 6. NEUT, LY, LY/%, SCR 7. PLT, CRP, ALT, AST, TBIL, ALP, GGT, BUN, LDH 8. Death rate | 1.(6 ± 2)d 2.(5 ± 1.10)d 3.(6 ± 2.12)d 4.(4 ± 1.54)d 5.Most of them still had lesions, and only 1 mild case was cured 6.P<0.05 7.P>0.05 8. Not mentioned |
Basic characteristics of the included studies (CS).
MT, mild type; CT, common type; ST, serious type; WT, western treatment, WT: 1. antiviral; 2. anti-infection/anti-inflammatory/antibiotics; 3. immunoregulation; 4. gastrointestinal regulation; 5. relieving cough and asthma; 6. oxygen therapy; 7. glucocorticoid; 8. nutritional support; 9. nlgesics; 10. liver protection; 11. anti-anxiety.
Analysis of the Law of Prescription Use in TCM
Frequency Analysis of Single Chinese Herbal Medicine
The statistical analysis showed that 34 traditional Chinese medicine prescriptions, involving 106 traditional Chinese medicines, were used in 20 clinical studies. The frequency of traditional Chinese medicine use was sorted. The top three drugs were Glycyrrhizae Radix Et Rhizoma (Gancao), Ephedrae Herba (Mahuang), and Armeniacae Semen Amarum (Kuxingren). Ephedrae Herba (Mahuang) aids in freeing lung, relieving cough and asthma and releasing exterior syndrome; Armeniacae Semen Amarum (Kuxingren) helps to depress qi and relieve cough and asthma; and Glycyrrhizae Radix Et Rhizoma (Gancao) facilitates in relieving cough and reducing sputum and coordinating of drugs. The three drugs are commonly used for cough and sputum and are also the basic components of Maxing Ganshi decoction in traditional Chinese medicine to treat cough and asthma. In the included prescriptions, 24 drugs were found with a frequency of ≥5 (Table 3). According to the traditional Chinese medicine category to sort out the 106 traditional Chinese medicines, the top 3 most frequently used are heat-clearing medicines, exterior syndrome-relieving medicines and phlegm-resolving and cough and asthma-relieving medicines, followed by damp-resolving medicines, tonify medicines, and damp-draining diuretic medicines. The details are presented in Table 4.
Table 3
| No. | Chinese name | Latin name | Freq. | No. | Chinese name | Latin name | Freq. |
|---|---|---|---|---|---|---|---|
| 1 | Gancao | Glycyrrhizae Radix Et Rhizoma | 18 | 13 | Renshen | Ginseng Radix Et Rhizoma | 8 |
| 2 | Mahuang | Ephedrae Herba | 16 | 14 | Shigao | Gypsum Fibrosum | 8 |
| 3 | Kuxingren | Armeniacae Semen Amarum | 14 | 15 | Taoren | Persicae Semen | 7 |
| 4 | Huangqin | Scutellariae Radix | 12 | 16 | Chaihu | Bupleuri Radix | 7 |
| 5 | Cangzhu | Atractylodis Rhizoma | 12 | 17 | Lianqiao | Forsythiae Fructus | 7 |
| 6 | Fuling | Poria | 11 | 18 | Huangqi | Astragali Radix | 6 |
| 7 | Banxia | Pinelliae Rhizoma | 11 | 19 | Yiyiren | Coicis Semen | 6 |
| 8 | Binglang | Arecae Semen | 10 | 20 | Dahuang | Rhei Radix Et Rhizoma | 5 |
| 9 | Chenpi | Citri Reticulatae Pericarpium | 9 | 21 | Baizhu | Atractylodis Macrocephalae Rhizoma | 5 |
| 10 | Houpo | Magnoliae Officinalis Cortex | 9 | 22 | Baishao | Paeoniae Radix Alba | 5 |
| 11 | Caoguo | Tsaoko Fructus | 8 | 23 | Zhimu | Anemarrhenae Rhizoma | 5 |
| 12 | Guanghuoxiang | Pogostemonis Herba | 8 | 24 | Chantui | Cicadae Periostracum (Periostracum Cicadae Cryptotympana atrata Fabricius) | 5 |
Frequency of traditional Chinese herbal medicine (frequency≥5).
Table 4
| No | Types | Freq. | Types of Medicines |
|---|---|---|---|
| 1 | Heat-clearing medicines | 65 | 23 |
| 2 | Exterior syndrome-relieving medicines | 55 | 16 |
| 3 | Phlegm-resolving and cough and asthma-relieving medicines | 48 | 15 |
| 4 | Damp-resolving medicines | 43 | 7 |
| 5 | Tonify medicines | 42 | 15 |
| 6 | Damp-draining diuretic medicines | 30 | 9 |
| 7 | Qi-regulating medicines | 23 | 4 |
| 8 | Blood-activating and stasis-resolving medicines | 11 | 4 |
| 9 | Interior-warming medicines | 8 | 3 |
| 10 | Resolving wind-damp medicines | 6 | 4 |
| 11 | Astringent medicines | 5 | 3 |
| 12 | Purgative medicines | 5 | 1 |
| 13 | Clearing away toxin and killing parasites medicines | 2 | 2 |
| 14 | Liver-calming and wind-extinguishing medicines | 1 | 1 |
Frequency of types of traditional Chinese herbal medicine.
The frequency of application of Glycyrrhizae Radix Et Rhizoma (gancao) has not been counted in the statistics, because of Glycyrrhizae Radix Et Rhizoma (gancao) commonly used as harmonizing herb in TCM decoctions.
Analysis of the Association Rules of Traditional Chinese Herbal Medicine
The association rules of traditional Chinese medicine for the included prescriptions were analyzed. The support was set to 20%. The results showed 10 associations of traditional Chinese medicine with a confidence of above 0.8. The association of traditional Chinese medicine with a confidence of 1 was Gypsum Fibrosum (Shigao)->Armeniacae Semen Amarum (Kuxingren), Tsaoko Fructus (Caoguo) -> Arecae Semen (Binglang). The association of traditional Chinese medicine with a confidence level of above 0.86 was Gypsum Fibrosum (Shigao) -> Ephedrae Herba (Mahuang), Gypsum Fibrosum (Shigao), Armeniacae Semen Amarum (Kuxingren) -> Ephedrae Herba (Mahuang), Ephedrae Herba (Mahuang), Arecae Semen (Binglang) -> Atractylodis Rhizoma (Cangzhu), Ephedrae Herba (Mahuang), Arecae Semen (Binglang) -> Armeniacae Semen Amarum (Kuxingren), Atractylodis Rhizoma (Cangzhu), Arecae Semen (Binglang) -> Ephedrae Herba (Mahuang). Table 5 presents the analysis of specific association rules.
Table 5
| No. | Chinese name | Latin name | Confidence coefficient |
|---|---|---|---|
| 1 | Shigao -> Kuxingren | Gypsum Fibrosum -> Armeniacae Semen Amarum | 1 |
| 2 | Caoguo-> Binglang | Tsaoko Fructus -> Arecae Semen | 1 |
| 3 | Shigao -> Mahuang | Gypsum Fibrosum -> Ephedrae Herba | 0.875 |
| 4 | Shigao, Kuxingren -> Mahuang | Gypsum Fibrosum, Armeniacae Semen Amarum -> Ephedrae Herba | 0.875 |
| 5 | Mahuang, Binglang -> Cangzhu | Ephedrae Herba, Arecae Semen -> Atractylodis Rhizoma | 0.875 |
| 6 | Mahuang, Binglang -> Kuxingren | Ephedrae Herba, Arecae Semen-> Armeniacae Semen Amarum | 0.875 |
| 7 | Cangzhu, Binglang ->Mahuang | Atractylodis Rhizoma, Arecae Semen -> Ephedrae Herba | 0.875 |
| 8 | Kuxingren -> Mahuang | Armeniacae Semen Amarum-> Ephedrae Herba | 0.857 |
| 9 | Banxia -> Fuling | Pinelliae Rhizoma -> Poria | 0.82 |
| 10 | Fuling -> Banxia | Poria -> Pinelliae Rhizoma | 0.82 |
Analysis of the association rules of traditional Chinese herbal medicine.
Analysis of Chinese Herbal Medicine Combinations Network
The relationship among different drug combinations was visualized using the network display function of the traditional Chinese medicine inheritance auxiliary system. The results showed that Ephedrae Herba (Mahuang)–Armeniacae Semen Amarum (Kuxingren) had the highest support, as the most common core combination, followed by Pinelliae Rhizoma (Banxia)–Poria (Fuling), Ephedrae Herba (Mahuang)–Glycyrrhizae Radix Et Rhizoma (Gancao) and Ephedrae Herba (Mahuang)–Atractylodis Rhizoma (Cangzhu). This result indicates that commonly used clinical treatments for NCP involve depressing qi, relieving cough, eliminating dampness and eliminating phlegm. The Chinese herbal medicine combinations network is presented in Figure 2.
Figure 2
Analysis of Application of Classical Prescriptions of TCM
Studies involving the application of classical prescriptions of TCM were collected and summarized. Six studies were obtained. Among these classical prescriptions, Da Yuan decoction and Ganlu Xiaodu pill were created by doctors Wu Youke (Ming Dynasty and Ye Tianshi (Qing Dynasty) and who studied in epidemic exogenous febrile diseases, while Maxing Ganshi decoction was created by doctor Zhang Zhongjing (Han Dynasty) who researched on exogenous cold induced febrile diseases. Modern prescriptions are mostly added and subtracted by classical prescriptions. For example, the Qingfei Paidu decoction recommended by the State Administration of Traditional Chinese Medicine is based on Maxing Ganshi decoction, Shegan Mahuang decoction, Wuling powder and Xiao Chaihu decoction. The classical prescriptions with a literature frequency of ≥ 2 are presented in Table 6.
Table 6
| No. | Classical Prescriptions of TCM | Components Latin name(Chinese name) | Source(year of completion) | Freq. | Application of cases |
|---|---|---|---|---|---|
| 1 | Ganlu Xiaodu Pill | Amomi Fructus Rotundus(Doukou), Pogostemonis Herba(Guanghuoxiang), Acori Tatarinowii Rhizoma(Shichangpu), Menthae Haplocalycis Herba(Bohe), Forsythiae Fructus(Lianqiao), Belamcandae Rhizoma(Shegan), Fritillariae Cirrhosae Bulbus(Chuanbeimu), Scutellariae Radix (Huangqin), Artemisiae Scopariae Herba (Yinchen), Talcum(Huashi), Akebiae Caulis(Mutong) | Secret of Medical Efficacy AD 1831 | 3 | 40 |
| 2 | Maxing Ganshi Decoction | Ephedrae Herba(Mahuang), Armeniacae Semen Amarum(Kuxingren), Gypsum Fibrosum(Shigao), Glycyrrhizae Radix Et Rhizoma (Gancao) | Treatise on Febrile Diseases AD 200 | 2 | 80 |
| 3 | Huopo Xialing Decoction | Pogostemonis Herba (Guanghuoxiang), Sojae Semen Praeparatum (Dandouchi), Amomi Fructus Rotundus (Doukou), Magnoliae Officinalis Cortex(Houpo), Pinelliae Rhizoma (Banxia), Armeniacae Semen Amarum(Kuxingren), Poria (Fuling), Polyporus(Zhuling), Alismatis Rhizoma(Zexie), Coicis Semen (Yiyiren) | Original Medical Theory AD 1861 | 2 | 45 |
| 4 | Da Yuan Decoction | Arecae Semen (Binglang), Magnoliae Officinalis Cortex (Houpo), Tsaoko Fructus (Caoguo), Anemarrhenae Rhizoma(Zhimu), Paeoniae Radix Alba(Baishao), Scutellariae Radix (Huangqin), Glycyrrhizae Radix Et Rhizoma(Gancao) | Treatise on Acute Epidemic Febrile Diseases AD 1642 | 2 | 42 |
| 5 | Haoqin Qingdan Decoction | Artemisiae Annuae Herba(Qinghao), Bambusae Caulis In Taenias(Zhuru), Pinelliae Rhizoma(Banxia), Poria (Fuling), Scutellariae Radix (Huangqin), Aurantii Fructus(Zhiqiao), Citri Reticulatae Pericarpium (Chenpi), Talcum(Huashi), Indigo Naturalis(Qingdai), Glycyrrhizae Radix Et Rhizoma(Gancao) | Revisiting of Treatise on Acute Epidemic Febrile Diseases AD 1956 | 2 | 25 |
| 6 | Xuanbai Chengqi Decoction | Gypsum Fibrosum (Shigao), Rhei Radix Et Rhizoma (Dahuang), Armeniacae Semen Amarum(Kuxingren), Trichosanthis Fructus (Gualou) | Item Differentiation of Warm Febrile Diseases AD 1798 | 2 | 18 |
| 7 | Tingli Dazao Xiefei Decoction | Descurainiae Semen Lepidii Semen (Tinglizi), Jujubae Fructus(Dazao) | Synopsis of Golden Chamber AD 200 | 2 | 18 |
The commonly used classical prescriptions of TCM for NCP.
Analysis of Application of Chinese Patent Medicine
Given its convenient application, Chinese patent medicine has gained increasing research attention. An analysis of the use of Chinese patent medicine in 20 clinical studies showed that Lianhua Qingwen capsules/granules are the most widely used. These capsules have been widely studied to verify their clinical efficacy. Lianhua Qingwen can act on coronavirus through multiple components, targets and pathways via their broad-spectrum antiviral, antibacterial and antipyretic; cough relief; sputum reduction and immune regulation effects (). In the treatment of NCP, Xuebijing and other traditional Chinese medicine injections have been used several times. Xuebijing can antagonize endotoxins (; ) and inhibit the excessive release of inflammatory mediators, such as interferon and interleukin (), thereby inhibiting inflammation and enhancing immunity (). The academician Zhang Boli emphasized that the early application of traditional Chinese medicine injection can play a vital role in treating critical patients (). Table 7 presents The commonly used Chinese patent medicine for NCP.
Table 7
| No. | Chinese patent medicine | Components Latin name(Chinese name) | Freq. | Prop. |
|---|---|---|---|---|
| 1 | Lianhua Qingwen capsule/granule | Forsythiae Fructus(Lianqiao), Lonicerae Japonicae Flos (Jinyinhua), Ephedrae Herba(Mahuang), Armeniacae Semen Amarum(Kuxingren), Gypsum Fibrosum (Shigao), Isatidis Radix(Banlangen), Dryopteridis Crassirhizomatis Rhizoma(Mianma Guanzhong), Houttuyniae Herba(Yuxingcao), Pogostemonis Herba (Guanghuoxiang), Rhei Radix Et Rhizoma(Dahuang), Rhodiolae Crenulatae Radix Et Rhizoma(Hongjingtian) | 7 | 35.00% |
| 2 | Xue Bi Jing Injection | Carthami Flos(Honghua), Paeoniae Radix Rubra (Chishao), ChuanxiongRhizoma (Chuanxiong), Salviae Miltiorrhizae Radix Et Rhizoma (Danshen), Angelicae Sinensis Radix(Danggui) | 3 | 15.00% |
| 3 | Shufeng Jiedu Capsule | Polygoni Cuspidati Rhizoma Et Radix (Huzhang), Forsythiae Fructus (Lianqiao), Isatidis Radix (Banlangen), Bupleuri Radix (Chaihu), Herba Patriniae(Baijiangcao), Verbenae Herba (Mabiancao), Phragmitis Rhizoma (Lugen), Glycyrrhizae Radix Et Rhizoma (Gancao) | 3 | 15.00% |
The commonly used Chinese patent medicine for NCP.
Investigation of the Observation Indicators
In 20 studies on the treatment of NCP, the most commonly used clinical observation and evaluation indices was fever improvement time, followed by cough improvement time, shortness of breath improvement time, chest CT, and TCM syndrome scale score. Some articles also used the disappearance rate of other accompanying symptoms and CRP examination as observation indices. From Table 1, we can see the fever improvement time in the trial group was significantly shorter than that in the control group. In Table 8, we listed the Chinese name, Latin name in Chinese pharmacopeia, and Name in Medicinal Plant Names Services.
Table 8
| No. | Chinese name | Latin name in Chinese pharmacopeia | Name in Medicinal Plant Names Services (MPNS) |
|---|---|---|---|
| 1 | Baijiangcao | Herba Patriniae | Patrinia scabiosifolia Link |
| 2 | Baishao | Paeoniae Radix Alba | Paeonia lactiflora Pall. |
| 3 | Baizhi | Angelicae Dahuricae Radix | Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav. |
| 4 | Baizhu | Atractylodis Macrocephalae Rhizoma | Atractylodes macrocephala Koidz. |
| 5 | Banlangen | Isatidis Radix | Isatis tinctoria L. |
| 6 | Banxia | Pinelliae Rhizoma | Pinellia ternata (Thunb.) Makino |
| 7 | Binglang | Arecae Semen | Areca catechu L. |
| 8 | Bohe | Menthae Haplocalycis Herba | Mentha canadensis L. |
| 9 | Cangzhu | Atractylodis Rhizoma | Atractylodes lancea (Thunb.) DC. |
| 10 | Caoguo | Tsaoko Fructus | Lanxangia tsao-ko (Crevost & Lemarié) M.F.Newman & Skornick. |
| 11 | Chaihu | Bupleuri Radix | Bupleurum chinense DC. |
| 12 | Chantui | Cicadae Periostracum (Periostracum Cicadae Cryptotympana atrata Fab- ricius) | —— |
| 13 | Chenpi | Citri Reticulatae Pericarpium | Citrus × aurantium L. |
| 14 | Chishao | Paeoniae Radix Rubra | Paeonia anomala subsp. veitchii (Lynch) D.Y.Hong & K.Y.Pan |
| 15 | Chuanbeimu | Fritillariae Cirrhosae Bulbus | Fritillaria cirrhosa D.Don |
| 16 | Chuanxiong | Chuanxiong Rhizoma | Conioselinum anthriscoides 'Chuanxiong' |
| 17 | Dahuang | Rhei Radix Et Rhizoma | Rheum palmatum L. |
| 18 | Dandouchi | Sojae Semen Praeparatum | Glycine max (L.) Merr. |
| 19 | Danggui | Angelicae Sinensis Radix | Angelica sinensis (Oliv.) Diels |
| 20 | Danshen | Salviae Miltiorrhizae Radix Et Rhizoma | Salvia miltiorrhiza Bunge |
| 21 | Daqingye | Isatidis Folium | Isatis tinctoria L.(Folium Isatidis) |
| 22 | Dazao | Jujubae Fructus | Ziziphus jujuba Mill. |
| 23 | Dihuang | Rehmanniae Radix | Rehmannia glutinosa (Gaertn.) DC. |
| 24 | Doukou | Amomi Fructus Rotundus | Alpinia hainanensis K.Schum. |
| 25 | Fangfeng | Saposhnikoviae Radix | Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk. |
| 26 | Fengfang | Vespae Nidus | —— |
| 27 | Fuling | Poria | Smilax glabra Roxb. ( Poria cocos (Schw. ) Wolf.) |
| 28 | Fuzi | Aconiti Lateralis Radix Praeparata | Aconitum carmichaeli Debeaux (Radix Aconiti Lateralis Preparata) |
| 29 | Gancao | Glycyrrhizae Radix Et Rhizoma | Glycyrrhiza uralensis Fisch. ex DC. |
| 30 | Ganjiang | Zingibneris Rhizoma | Zingiber officinale Roscoe (Rhizoma Zingiberis) |
| 31 | Gegen | Puerariae Lobatae Radix | Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep |
| 32 | Gualou | Trichosanthis Fructus | Trichosanthes kirilowii Maxim. |
| 33 | Guanghuoxiang | Pogostemonis Herba | Pogostemon cablin (Blanco) Benth. |
| 34 | Guizhi | Cinnamomi Ramulus | Cinnamomum cassia (L.) J.Presl |
| 35 | Honghua | Carthami Flos | Carthamus tinctorius L. |
| 36 | Hongjingtian | Rhodiolae Crenulatae Radix Et Rhizoma | Rhodiola crenulata (Hook.f. & Thomson) H.Ohba |
| 37 | Hongshen | Ginseng Radix Et Rhizoma Rubra | Panax ginseng C.A.Mey. |
| 38 | Houpo | Magnoliae Officinalis Cortex | Magnolia officinalis Rehder & E.H.Wilson |
| 39 | Huanglian | Coptidis Rhizoma | Coptis chinensis Franch. |
| 40 | Huangqi | Astragali Radix | Astragalus mongholicus Bunge |
| 41 | Huangqin | Scutellariae Radix | Scutellaria baicalensis Georgi |
| 42 | Huashi | Talcum | —— |
| 43 | Huzhang | Polygoni Cuspidati Rhizoma Et Radix | Reynoutria japonica Houtt. |
| 44 | Jiangcan | Bombyx Batryticatus | —— |
| 45 | Jianghuang | Curcumae Longae Rhizoma | Curcuma longa L. |
| 46 | Jinyinhua | Lonicerae Japonicae Flos | Lonicera japonica Thunb. |
| 47 | Kuxingren | Armeniacae Semen Amarum | Prunus armeniaca L. |
| 48 | Lianqiao | Forsythiae Fructus | Forsythia suspensa (Thunb.) Vahl |
| 49 | Lugen | Phragmitis Rhizoma | Phragmites australis subsp. australis |
| 50 | Mabiancao | Verbenae Herba | Verbena officinalis L. |
| 51 | Mahuang | Ephedrae Herba | Ephedra sinica Stapf |
| 52 | Maidong | Ophiopogonis Radix | Ophiopogon japonicus (Thunb.) Ker Gawl. |
| 53 | Mianma Guanzhong | Dryopteridis Crassirhizomatis Rhizoma | Dryopteris crassirhizoma Nakai |
| 54 | Moyao | Myrrha | Commiphora myrrha (T.Nees) Engl. |
| 55 | Mudanpi | Moutan Cortex | Paeonia × suffruticosa Andrews |
| 56 | Mutong | Akebiae Caulis | Akebia quinata (Thunb. ex Houtt.) Decne. |
| 57 | Niubangzi | Arctii Fructus | Arctium lappa L. |
| 58 | Pugongying | Taraxaci Herba | Taraxacum mongolicum Hand.-Mazz. |
| 59 | Qianhu | Peucedani Radix | Kitagawia praeruptora (Dunn) Pimenov |
| 60 | Qingdai | Indigo Naturalis | Persicaria tinctoria (Aiton) Spach |
| 61 | Qinghao | Artemisiae Annuae Herba | Artemisia annua L. |
| 62 | Renshen | Ginseng Radix Et Rhizoma | Panax ginseng C.A.Mey. |
| 63 | Sangbaipi | Mori Cortex | Morus alba L. |
| 64 | Shancigu | Cremastrae Pseudobulbus Pleiones Pseudobulbus | Pleione yunnanensis (Rolfe) Rolfe |
| 65 | Shegan | Belamcandae Rhizoma | Iris domestica (L.) Goldblatt & Mabb. |
| 66 | Shengjiang | Zingiberis Rhizoma Recens | Zingiber officinale Roscoe |
| 67 | Shengma | Cimicifugae Rhizoma | Actaea cimicifuga L. |
| 68 | Shichangpu | Acori Tatarinowii Rhizoma | Acorus calamus var. angustatus Besser |
| 69 | Shigao | Gypsum Fibrosum | —— |
| 70 | Taizishen | Pseudostellariae Radix | Pseudostellaria heterophylla (Miq.) Pax |
| 71 | Taoren | Persicae Semen | Prunus persica (L.) Batsch |
| 72 | Tinglizi | Descurainiae Semen Lepidii Semen | Descurainia sophia (L.) Webb ex Prantl |
| 73 | Weilingxian | Clematidis Radix Et Rhizoma | Clematis chinensis Osbeck |
| 74 | Wumei | Mume Fructus | Prunus mume (Siebold) Siebold & Zucc. |
| 75 | Wuweizi | Schisandrae Chinensis Fructus | Schisandra chinensis (Turcz.) Baill. |
| 76 | Xinyi | Magnoliae Flos | Magnolia biondii Pamp. |
| 77 | Xixiancao | Siegesbeckiae Herba | Sigesbeckia orientalis L. |
| 78 | Xixin | Asari Radix Et Rhizoma | Asarum sieboldii Miq. |
| 79 | Xuanshen | Scrophulariae Radix | Scrophularia ningpoensis Hemsl. |
| 80 | Yinchen | Artemisiae Scopariae Herba | Artemisia capillaris Thunb. |
| 81 | Yiyiren | Coicis Semen | Coix lacryma-jobi var. ma-yuen (Rom.Caill.) Stapf |
| 82 | Yuxingcao | Houttuyniae Herba | Houttuynia cordata Thunb. |
| 83 | Zexie | Alismatis Rhizoma | Alisma plantago-aquatica subsp. orientale (Sam.) Sam. |
| 84 | Zhebeimu | Fritiliariae Thunbergil Bulbus | Fritillaria thunbergii Miq. |
| 85 | Zhimu | Anemarrhenae Rhizoma | Anemarrhena asphodeloides Bunge |
| 86 | Zhiqiao | Aurantii Fructus | Citrus trifoliata L. |
| 87 | Zhuling | Polyporus (Polyporus umbellatus(Pers.) Fr.) | —— |
| 88 | Zhuru | Bambusae Caulis In Taenias | Bambusa beecheyana Munro |
| 89 | Ziwan | Asteris Radix Et Rhizoma | Aster tataricus L.f. |
Drug name comparison table.
The drugs were listed in the order of their Chinese name.
The top frequency that search term appeared in medicinal plant literature was chosen.
—— MPNS could not match the search term.
Discussion
On the discussion of epidemic, the ancient Chinese doctor Wu Youke from the Ming Dynasty pointed out it was caused by epidemic pathogenic evils. Given its strong infectivity, disease location and clinical characteristics, NCP can be named “pulmonary epidemic disease” (). The main consensus regarding its pathogenesis is that the virus invades the lungs and causes vital qi deficiency. The pathological nature is dampness, heat, toxin, deficiency and stasis.
This study mainly uses bibliometrics and data mining methods to obtain a systematic summary of clinical studies published at this stage and systematically analyses the published information, research design, intervention measures and observation indicators. A summary of the research methods indicates that only 2 RCTs were conducted. Most of the studies were CCTs and CSs. Considering the large number of patients and the rapid spread of the epidemic, the shortage of medical resources has led to the unconditional implementation of RCT research. The treatment of patients is the first priority at this time.
Regarding the time distribution of publications, the time that research on traditional Chinese medicine treatment of NCP was conducted synchronized with the epidemic. Furthermore, the symptom improvement rate and symptom scores in the observation and evaluation indicators fully reflect the characteristics of the judgment standard of clinical efficacy of traditional Chinese medicine. The total number of observation cases also reflects the high participation of traditional Chinese medicine in this anti-epidemic treatment. A clear understanding of Chinese herbal medicines use has been achieved through the data mining and analysis of prescriptions for treatment of NCP. In addition to Glycyrrhizae Radix Et Rhizoma (Gancao), Ephedrae Herba (Mahuang), Armeniacae Semen Amarum (Kuxingren) Atractylodis Rhizoma (Cangzhu) and Scutellariae Radix (Huangqin) are frequently used. An analysis of drug categories showed that heat-clearing medicine, exterior syndrome-relieving medicines, phlegm-resolving and cough and asthma-relieving medicines, and humidifying drugs are frequently used. This finding suggests that dampness and toxin accumulating in the lung are the main pathogenesis of NCP. Ephedrae Herba (Mahuang)-Armeniacae Semen Amarum (Kuxingren) had the highest support and high confidence in the association rules, which reflects the classic compatibility of Maxing Shigan decoction. About the high frequency Chinese herbal medicines, most of it enters the lung meridian or spleen meridian. Chinese medicine recognizes that NCP mainly involves the lung. The spleen is the source of phlegm, and the lung is the sputum storage position, phlegm and dampness caused by lung and spleen disease. The results of clinical application analysis of Chinese patent medicines reflect the participation in clinical treatment. Given their wide range of applications and convenient application, Chinese patent medicines play an important role in clinical treatment of the epidemic in China. Traditional Chinese medicine for treatment of NCP is worthy of global attention.
Our study has several limitations. Randomized controlled trials are the most commonly used to judge the effectiveness of interventions. This review only included two RCTs. And they did not mention blinding method. In addition, the interventions, treatment courses, and observation indicators of each study were quite different, so meta-analysis cannot be done. High-quality RCTs on the effectiveness and safety of traditional Chinese medicine in the treatment of new coronary pneumonia need further study.
Funding
We are very grateful for the financial support from the Special Research Project of Traditional Chinese Medicine Industry (201107006) and the School-level scientific research project of Tianjin University of Traditional Chinese Medicine (XJ201801).
Statements
Author contributions
ZZ conceived and wrote the manuscript draft. SF designed the study and revised the manuscript. NG drafted the manuscript. YW was responsible for data collection. PC helped data management. YT was in charge of statistical analysis of data. All authors contributed to the article and approved the submitted version.
Acknowledgments
We gratefully acknowledged the cooperation of all research staff and participants.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.560448/full#supplementary-material
Abbreviations
NCP, new coronary pneumonia; CCT, clinical control trials; RCT, randomized controlled trials; CS, case series studies; TCM, Traditional Chinese medicine.
References
1
BinY. F.JiP.LiangX. D.LiuG. N.ZhangJ. F. (2020). Clinical characteristics of 55 hospitalized patients with COVID-19 in Wuhan, China. J. Guangxi Med. Univ.37 (02), 338–342. doi: 10.16190/j.cnki.45-1211/r.2020.02.034
2
ChengD. Z.LiY. (2020). Clinical Effectiveness and Case Analysis in 54 NCP Patients Treated with Lanhuaqingwen Granules. World Chin. Med.15 (02), 150–154. doi: 10.3969/j.issn.1673-7202.2020.02.006
3
ChengD. Z.WangW. J.LiY.WuX. D.ZhouB.SongQ. Y. (2020). Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Tianjin J. Trad. Chin. Med. 37 (05), 509–516. doi: 10.11656/j.issn.1672-1519.2020.05.06
4
DiaoY. F.SunL.ChengS. X.TuY.ZhangS. (2015). Effects of Xuebijing injection in treatment of severe pneumonia. China J. Emergency Resuscitation Dis. Med.10 (4), 337–339. doi: 10.3969/j.issn.1673-6966.2015.04.012
5
DingX. J.ZhangY.HeD. C.ZhangMyTanY. J.YvA. R.et al. (2020). Clinical Effect and Mechanism of Qingfei Touxie Fuzheng Recipe in the Treatment of Novel Coronavirus Pneumonia. Herald Med.39 (05), 640–644. doi: 10.3870/j.issn.1004-0781.2020.05.012
6
Dingxiangyuan (2020). Real-time dynamics of new coronavirus infection pneumonia. Available at: https://ncov.dxy.cn/ncovh5/view/pneumonia [2020-04-02].
7
DuanC.XiaW. G.ZhengC. J.SunG. B.LiZ. L.LiQ. L.et al. (2020). Clinical Observation of Jinhua Qinggan Granule in Treating New Coronavirus Infection Pneumonia. J. Trad. Chin. Med.1–5.
8
FangL.ZhuQ. G.ChengW.ZhanC.FangX. M.GuoC. Y.et al. (2020). Retrospective analysis on 308 cases of COVID-19 and clinical application program of Kangyi Qiangshen Gong exercise prescription. Shanghai J. Trad. Chin. Med.54 (05), 40–45. doi: 10.16305/j.1007-1334.2020.05.095 [2020-04-23].
9
FuX. X.LinL. P.TanX. H. (2020). Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and Western Medicine. Trad. Chin. Drug Res. Clin. Pharmacol.31 (05), 600–604. doi: 10.19378/j.issn.1003-9783.2020.05.016
10
GongX.MouF. Z.WeiD. R.DouL.GongX. Y.WangT.et al. (2020). The clinical characteristics and medication analysis of Corona Virus Disease 2019. World Chin. Med.15 (06), 819–826. doi: 10.3969/j.issn.1673-7202.2020.06.002
11
GuoJ. C.WanH. T. (2020). Discussion on the etiology, pathogenesis and treatment of new coronavirus pneumonia. J. Trad. Chin. Med.61 (13), 1118–1123. doi: 10.13288/j.11-2166/r.2020.13.003
12
HuZ. Q.LiZ. B.LiS. W.BieH. J.WangC. H.ZhaJ. L. (2020). Observation on Clinical Treatment of 19 Cases of Nanyang COVID-19(Common Type). Forum Trad. Chin. Med.35 (02), 22–24. doi: 10.13913/j.cnki.41-1110/r.2020.02.011
13
LingX. Y.TaoJ. L.SunX.YuanB. (2020). Exploring material basis and mechanism of Linhua Qingwen Prescription against coronavirus based on network pharmacology. Chin. Trad. Herbal Drugs51 (07), 1723–1730. doi: 10.7501/j.issn.0253-2670.2020.07.006
14
LvR. B.WangW. J.LiX. (2020). Clinical Observation on 63 Cases of Suspected New Coronavirus Pneumonia Treated by Lianhuaqingwen. J. Trad. Chin. Med.61 (8), 655–659. doi: 10.13288/j.11-2166/r.2020.08.003
15
National Health Commission of the People’s Republic of China (2020). Diagnosis and Treatment Plan of Novel Coronavirus Infection Pneumonia (edition 7). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
16
QvX. K.HaoS. L.MaJ. H.WeiG. Y.SongK. Y.TangC.et al. (2020). Observation on clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsule in treatment of COVID-19. Chin. Trad. Herbal Drugs51 (05), 1167–1170. doi: 10.7501/j.issn.0253-2670.2020.05.011
17
ShiJ.YangZ. G.YeC.ChenS. S.LuY. F.LvY.et al. (2020). Clinical observation on 49 cases of non-critical COVID-19 in Shanghai treated by integrated traditional Chinese and western medicine. Shanghai J. Trad. Chin. Med.54 (04), 30–35. doi: 10.16305/j.1007-1334.2020.04.095
18
Tencent News (2020a). Zhong Nanshan affirmed the effect of Chinese medicine on the treatment of new coronavirus pneumonia: Effective Chinese medicine can be promoted abroad. Available at: http://m.v.qq.com/play/play.html?vid=q0950t2va9i&url_from=share&second_share=0&share_from=copy.
19
Tencent News (2020b). Making good use of Chinese medicine injections for critically ill patients. Available at: https://xw.qq.com/amphtml/20200302A03TOA00, 2020-03-01.
20
TianJ.YangS.SongD. D. (2019). Progress in clinical efficacy of Xuebijing in treatment of severe pneumonia. J. Clin. Pulmon. Med.24 (05), 96–99+104. doi: 10.3969/j.issn.1009-6663.2019.05.022
21
WangY. L.YangX. D.LiuY. P.ZhangJ.FengY. F.ShangL.et al. (2020). Preliminary clinical effect analysis of the treatment of novel coronavirus pneumonia by internal administration of traditional Chinese medicine plus fumigation and absorption combined with super dose of vitamin C in treating NOVID-19. J. Xi’an Jiaotong Univ. (Med. Sci.)1–7.
22
WangT.ShiL.ChenY. Y.FangY. K.YangW.DuanX. Z.et al. (2020). Clinical Efficacy Analysis of 50 Cases of Corona Virus Disease 2019 in Traditional Chinese Medicine. Jilin J. Chin. Med.40 (03), 281–285. doi: 10.13463/j.cnki.jlzyy.2020.03.001
23
WangY. (2019). Clinical Efficacy of Xuebijing in Patients with Severe Pneumonia and Its Effects on Inflammatory Mediators. China J. Pharm. Economics7, 98–100. doi: 10.12010/j.issn.1673-5846.2019.07.025
24
XiaW. G.AnC. Q.ZhengC. J.ZhangJ. X.HuangM.WangY.et al. (2020). Clinical Observation on 34 Patients with Novel Coronavirus Pneumonia (COVID-19) Treated with Intergrated Traditional Chinese and Western Medicine. J. Trad. Chin. Med.61 (05), 375–382. doi: 10.13288/j.11-2166/r.2020.05.002
25
XiaoQ.JiangY. J.WuS. S.WangY.AnJ.XuW. P.et al. (2020). Analysis of the Value of Chinese Medicine Shufeng Jiedu Capsule Combined with Abidor in the Treatment of Mild New Coronavirus Pneumonia. J. Emergency Trad. Chin. Med.29 (05), 756–758. doi: 10.3969/j.issn.1004-745X.2020.05.002
26
YangQ.SunQ. G.JiangB.XvH. J.LuoM.XieP.et al. (2020). Retrospective clinical study on treatment of COVID-2019 patients with integrated traditional Chinese and Western medicine. Chin. Trad. Herbal Drugs51 (08), 2050–2054. doi: 10.7501/j.issn.0253-2670.2020.08.009
27
YangZ. J.YeL.ChenL.MiaoM. S.LiY. J. (2020). Treatment of COVID-19 with Qi GUI Ling Mixture. China J. Chin. Med.35 (06), 1151–1153+1176. doi: 10.16368/j.issn.1674-8999.2020.06.257
28
YaoK. T.LiuM. Y.LiX.HuangJ. H.CaiH. B. (2020). Retrospective Clinical Analysis on Treatment of Coronavirus Disease 2019 with Traditional Chinese Medicine Lianhua Qingwen. Chin. J. Exp. Trad. Med. Formulae26 (11), 8–12. doi: 10.13422/j.cnki.syfjx.20201099 [2020-04-22].
29
ZhangQ. Z. (2018). Observation on the curative effect of XueBijing on elderly patients with severe pneumonia. Modern Med. Health Res.2 (9), 43–44.
30
ZhuM.LvQ. Q.GuM. H.ChenY. C.WangJ.HuangZ. Q.et al. (2020). Clinical diagnosis and integrated treatment of traditional Chinese and western medicine for confirmed patients with coronavirus disease 2019 in Yangzhou area of Jiangsu Province. J. Clin. Med. Pract.24 (05), 1–5. doi: 10.7619/jcmp.202005001
Summary
Keywords
novel coronavirus pneumonia, traditional Chinese medicine, clinical research, Drug application rule, literature analysis
Citation
Zhou Z, Gao N, Wang Y, Chang P, Tong Y and Fu S (2020) Clinical Studies on the Treatment of Novel Coronavirus Pneumonia With Traditional Chinese Medicine—A Literature Analysis. Front. Pharmacol. 11:560448. doi: 10.3389/fphar.2020.560448
Received
08 May 2020
Accepted
12 August 2020
Published
10 September 2020
Volume
11 - 2020
Edited by
Michael Heinrich, UCL School of Pharmacy, United Kingdom
Reviewed by
Karl Tsim, Hong Kong University of Science and Technology, Hong Kong; Shailendra Shivaji Gurav, Goa College of Pharmacy, India
Updates
Copyright
© 2020 Zhou, Gao, Wang, Chang, Tong and Fu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shufei Fu, fushufei2012@163.com; Yi Tong, lyty215@126.com
†These authors share first authorship
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.